Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075231 · ClinicalTrials.gov registry record · Phase 2
A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects
A Phase 2 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00075231 is a Phase 2 study that has completed, run by Abbott. The registered enrollment target is 150 participants.
The verdict
NCT00075231, a Phase 2 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a simplified lopinavir-ritonavir based therapy will continue to keep the viral load to very low levels after initial treatment with a combination of Kaletra® (lopinavir/ritonavir) plus Combivir® (lamivudine/zidovudine).
Interventions
- DRUG Kaletra® (lopinavir/ritonavir)
- DRUG Combivir® (lamivudine, zidovudine)
- DRUG Sustiva® (efavirenz)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075231
The ClinicalTrials.gov registry entry for NCT00075231 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Kaletra® (lopinavir/ritonavir) is the first listed.
NCT00075231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00075231 about?
NCT00075231 is a clinical study titled "A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects". The purpose of this study is to determine whether a simplified lopinavir-ritonavir based therapy will continue to keep the viral load to very low levels after initial treatment with a combination of Kaletra® (lopinavir/ritonavir) plus Combivir® (lamivudine/zidovudine).
What is the current status of trial NCT00075231?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2003-12.
What interventions are being tested in trial NCT00075231?
The interventions under investigation include: Kaletra® (lopinavir/ritonavir) (DRUG), Combivir® (lamivudine, zidovudine) (DRUG), Sustiva® (efavirenz) (DRUG).
Who is sponsoring clinical trial NCT00075231?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.